Uniplus Biotech Private Limited - Due diligence report

A 360° intelligence report on Uniplus Biotech Private Limited: trust score, financial health, credit view, compliance, directors, growth and…

2010-01-22 Hapur, Uttar Pradesh Active Unlisted Active Compliant
Share
View plans
UB Uniplus Biotech Private Limited
Full Due-Diligence Report + Documents
  • Unlock all financial figures & 5-year trends
  • Full trust, health & credit-risk scores
  • Director details, charges & MCA documents
₹700 ₹349 50% off New user
Or enjoy up to 50% off with credits View credit packages
Company Credits – Starter
  • One credit unlocks this full due-diligence report
  • Use across any company’s report, anytime
  • Credits valid for 12 months
× ₹700 ₹279 = ₹2,790 60% off
Choose your own credit amount View credit packages

Uniplus Biotech Private Limited — 360° Intelligence Report

Generated from MCA filings & public records
83/100
Trust Score
Low Risk

Uniplus Biotech Private Limited is assessed as Low Risk with a Trust Score of 83/100. Uniplus Biotech Private Limited is an active private limited indian non-government company incorporated in 2010, operating in the Pharma sector. The company has shown revenue growth across its recent filed years. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a low compliance risk and low financial risk profile.

Report generated on 03 Jul 2026 from the latest processed filings. Uniplus Biotech Private Limited snapshot & full profile →

Financial Health › Strong
Overall Assessment CautionWeakNeutralGoodStrong Strong
Compliance › Strong

Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.

02

Score Card

Higher is safer · rule-based & explainable
Trust ScoreLow Risk
83/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreLow Risk
88/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreLow Risk
75/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreCaution Indicated
45/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
95/100
Board strength, DIN status, churn and network.
Growth ScoreLow Risk
75/100
Revenue, profit, asset and hiring momentum.
Distress ScoreModerate
65/100
Early-warning signals - higher means fewer warnings.
03

Financial Intelligence Dashboard

Standalone · 5 filed year(s)

Unlock the full 5-year financial dashboard with charts and year-wise figures.

Get full access

Scores and observations on this page are already computed from the real filings - only the underlying figures are locked.

04

Credit & Compliance Intelligence

Why the scores are what they are
Credit Risk Score: 45/100 Caution Indicated
  • Liabilities ≈ 38% EBITDA - stretched.
  • Open charges exceed net worth - secured lenders rank ahead.
  • Working-capital cover adequate.
  • Profitable - internal accruals available.

Charges position: 3 open (1.11 cr) · 0 satisfied (-).

Banking relationships (from registered charges)
LenderChargesAmount
Others1 48.0 cr
Canara Bank2 48.0 cr
Compliance Score: 88/100 Low Risk
  • Company status is Active as per MCA.
  • Balance sheet slightly behind (Mar 2024).
  • 1 active GST registration(s).
05

Director Intelligence

Stability score: 95/100
NameDIN / PANDesignationAppointedTenureDIN status
SUMAN LATA 01234567 Director 01/04/2018 6 yrs Approved
NIKETA TYAGI 01234567 Director 01/04/2018 6 yrs Approved
  • 2 directors on the board.
  • No disqualified or deactivated DINs.
  • Stable board - no exits in 3 years.
  • Average tenure above 5 years.
Director & KMP remuneration (FY 2023)
NameDesignationTotal remuneration
A K SharmaManaging Director2.4 cr
R MehtaWhole-time Director1.6 cr
S IyerCFO95.0 L

Remuneration is disclosed in the latest annual return. Unlock full report

06

Ownership & Group Intelligence

As per FY 2023 annual return
Promoter holding
64.27%
Public / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
-
Group entities
-
Capital events
2 allotment(s) · 5 transfer(s)

Promoters hold a dominant controlling stake - exact percentages are part of the full report.

Full shareholding pattern, group structure & capital events →

07

Risk Intelligence Center

Growth 75 · Distress 65
Growth signals & trust indicators
Revenue acceleration: +1.42 over 4 year(s).
Asset base grew 2.1x - capacity expansion.
Operating for 16+ years.
Active GST registration(s).
Distress signals & risk flags
Revenue declined year-on-year.
Outside liabilities up 24% in a year.
3 open charge(s) registered - assets are encumbered.
08

Stakeholder Verdicts

Vendor · Banker · Investor
Vendor due diligence80/100
Favourable indicators
Suitability as a supplier / customer counterparty.
  • Statutory record is clean.
  • 2 distress signal(s) - see Risk Center.
  • Financial filings available for verification.
Banker assessment65/100
Mixed indicators - deeper appraisal suggested
Indicative lending comfort for banks, NBFCs and trade credit.
  • Debt capacity assessed from filed statements.
  • 3 open charge(s) of 1.11 cr already registered.
  • Compliance record supports lending.
Investor view77/100
Positive growth indicators
Growth quality and scalability through an investor lens.
  • 2 growth signal(s) detected.
  • Margin and return trends computable from filings.
  • Management team looks stable.
09

MCA Filings & Events Timeline

Latest 15 events
21 Feb 2025
Charge created
Canara Bank - 8.00 Lakh
30 Sep 2024
Last AGM held
Annual general meeting
31 Mar 2024
Latest balance sheet
Filed with ROC
31 Mar 2022
Share transfer (FY 2022)
40800.00000000 shares to Suman Lata
Share transfer (FY 2022)
29000.00000000 shares to Niketa Tyagi
31 Dec 2021
Charge created
Canara Bank - 8.40 Lakh
25 Mar 2021
Charge created
Others - 95.00 Lakh
31 Mar 2020
Share transfer (FY 2020)
35800.00000000 shares to Bratpal Singh Tyagi
Share transfer (FY 2020)
5000.00000000 shares to Bratpal Singh Tyagi
Share transfer (FY 2020)
29000.00000000 shares to Amit Tyagi
30 Sep 2019
Director ceased
NIKETA TYAGI
10 Jun 2019
Director appointed
NIKETA TYAGI (Director)
Director ceased
AMIT TYAGI
23 Mar 2015
Securities allotted
64800.00 Equity Shares - 6.48 Lakh raised
31 May 2014
Securities allotted
64800.00 Equity Shares - 6.48 Lakh raised
10

Key Observations

Auto-generated from the data above
Revenue grew 0.86 over the last 4 financial year(s).
Net profit margin moved from 61% to 38%.
Debt-to-equity stands at 1.42 - leverage worth monitoring.
Net worth is positive.
Compliance record is strong - status, filings and flags are clean.
2 active director(s) / partner(s); board looks stable and experienced.
1 active GST registration(s) indicate ongoing business operations.
Promoters hold a dominant controlling stake as per the FY 2023 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
Capital has been raised through 2 security allotment(s) - amounts available in the full report.
11

Peers & Related Companies

Full peer comparison →
CompanyCINLocation
Magson Creative Apparel Private Limited U74999DL2017PTC312390 New Delhi, Delhi, India
Kalika Cold Storage Private Limited U74999WB2017PTC221732 Kolkata, West Bengal, India
Shubham Syncotex Private Limited U17124RJ1985PTC003413 Bhilwara, Rajasthan, India
Satvam Marketing Private Limited U74999GJ2016PTC093366 Ahmedabad, Gujarat, India
Deifik Automations Pvt Ltd U74999WB1995PTC072153 Kolkata, West Bengal, India
Utam Synercon Private Limited U74999PB2018PTC047352 Jalandhar, Punjab, India
Mac-Line India Private Limited U51505DL2002PTC114462 Delhi, Delhi, India
Treeore Private Limited U51909GJ2019PTC107886 Ahmedabad, Gujarat, India
12

Who Uses This Report

CA · CS · Banker · Investor · Vendor
Chartered Accountants (CA)

Verify Uniplus Biotech Private Limited before audits and certifications: compliance score 88/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.

Company Secretaries (CS)

Track statutory health of Uniplus Biotech Private Limited: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.

Bankers & NBFCs

Current banker verdict: Mixed indicators - deeper appraisal suggested. Credit risk score 45/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.

Investors & Analysts

Investor view: Positive growth indicators. Growth score 75/100, margin trends, ownership structure and peer set for Uniplus Biotech Private Limited - screening before a deeper diligence.

Vendors & Procurement Teams

Vendor verdict: Favourable indicators. Trust score 83/100, distress signals and MSME payment-delay disclosures - know whether Uniplus Biotech Private Limited pays its suppliers before you extend credit terms.

Lawyers & Compliance Teams

Litigation footprint (no cases on record), regulatory flags, charge documents trail and director networks for Uniplus Biotech Private Limited - groundwork for KYC, onboarding and disputes.

13

Frequently Asked Questions

Is Uniplus Biotech Private Limited an active company?

Uniplus Biotech Private Limited has MCA status “Active” with a compliance score of 88/100 (Low Risk).

Is Uniplus Biotech Private Limited financially healthy?

Uniplus Biotech Private Limited has a Financial Health Score of 75/100 (Low Risk) based on its filed financial statements.

Should I do business with Uniplus Biotech Private Limited?

Its overall Trust Score is 83/100 (Low Risk). Vendor verdict: Favourable indicators. Review the risk flags in the Risk Intelligence Center before deciding.

Who controls Uniplus Biotech Private Limited?

Promoters hold a dominant controlling stake - exact percentages are in the full report. 2 active director(s) are on record.

Does Uniplus Biotech Private Limited have loans or charges against its assets?

3 open charge(s) are registered against its assets.

Is Uniplus Biotech Private Limited up to date with its ROC filings?

Balance sheet slightly behind (Mar 2024). Overall compliance score: 88/100 (Low Risk).

Is it risky to lend to Uniplus Biotech Private Limited?

Its Credit Risk Score is 45/100 (Caution Indicated). Banker verdict: Mixed indicators - deeper appraisal suggested.

Disclaimer: This report is generated automatically from MCA filings and public records as available in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice. Verify from official sources and consult a qualified professional before any business, lending or investment decision. If you represent this company and believe any information is inaccurate or outdated, report it here and we will review promptly.